353 related articles for article (PubMed ID: 28092996)
21. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
22. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
24. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
[TBL] [Abstract][Full Text] [Related]
25. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
27. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
28. [The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment].
Li F; Xu Y; An G; Hu LP; Zhang YR; Li ZJ; Yuan WP; Cheng T; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):862-7. PubMed ID: 24171960
[TBL] [Abstract][Full Text] [Related]
29. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
[TBL] [Abstract][Full Text] [Related]
30. [Detection of del(17p13) among newly diagnosed multiple myeloma cases using cytoplasmic light chain immunofluorescence combined with FISH and its clinical significance].
Lu X; Chen L; Shi Q; Qiu H; Li J; Guo R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Oct; 37(10):1087-1091. PubMed ID: 32924107
[TBL] [Abstract][Full Text] [Related]
31. Natural history of multiple myeloma with de novo del(17p).
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
[TBL] [Abstract][Full Text] [Related]
32. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
33. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
34. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
35. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
36. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
[TBL] [Abstract][Full Text] [Related]
37. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
Klein U; Jauch A; Hielscher T; Hillengass J; Raab MS; Seckinger A; Hose D; Ho AD; Goldschmidt H; Neben K
Cancer; 2011 May; 117(10):2136-44. PubMed ID: 21523726
[TBL] [Abstract][Full Text] [Related]
38. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
[TBL] [Abstract][Full Text] [Related]
39. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
Avet-Loiseau H; Attal M; Campion L; Caillot D; Hulin C; Marit G; Stoppa AM; Voillat L; Wetterwald M; Pegourie B; Voog E; Tiab M; Banos A; Jaubert J; Bouscary D; Macro M; Kolb B; Traulle C; Mathiot C; Magrangeas F; Minvielle S; Facon T; Moreau P
J Clin Oncol; 2012 Jun; 30(16):1949-52. PubMed ID: 22547600
[TBL] [Abstract][Full Text] [Related]
40. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
